评估Nelipepimut-S治疗乳腺癌：关于新出现数据的简短报告。
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.
作者信息
Dillon Patrick M, Brenin Christiana M, Slingluff Craig L
机构信息
University of Virginia, Division of Hematology/Oncology, Charlottesville, VA 22908, USA.
University of Virginia, Department of Surgery, Charlottesville, VA 22908, USA.
出版信息
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
Abstract
Vaccine therapies for treatment and prevention of cancer have seen modest degrees of efficacy with wide variation related to the tumor type, vaccine type, adjuvants and clinical setting for their study. Over the course of the last two decades, various peptide vaccines for breast cancer have been studied. The current leading peptide vaccine for human application is a HER2-based vaccine known as Nelipepimut-S, which has demonstrated immune activity and promising clinical activity in some settings. This review covers the development of this newer peptide vaccine for both HER2 amplified and non-amplified breast cancer.
摘要
用于治疗和预防癌症的疫苗疗法疗效一般，其疗效因肿瘤类型、疫苗类型、佐剂以及研究的临床环境不同而有很大差异。在过去二十年中，人们对多种用于乳腺癌的肽疫苗进行了研究。目前用于人体的领先肽疫苗是一种基于HER2的疫苗，名为Nelipepimut-S，它在某些情况下已显示出免疫活性和有前景的临床活性。这篇综述涵盖了这种新型肽疫苗针对HER2扩增和非扩增乳腺癌的研发情况。
相似文献
1
Evaluating Nelipepimut-S in the Treatment of Breast Cancer: A Short Report on the Emerging Data.
Breast Cancer (Dove Med Press). 2020 Apr 3;12:69-75. doi: 10.2147/BCTT.S224758. eCollection 2020.
2
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response.
Immunotherapy. 2014;6(5):519-31. doi: 10.2217/imt.14.22.
3
The development and use of the E75 (HER2 369-377) peptide vaccine.
Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.
4
Initial safety analysis of a randomized phase II trial of nelipepimut-S + GM-CSF and trastuzumab compared to trastuzumab alone to prevent recurrence in breast cancer patients with HER2 low-expressing tumors.
Clin Immunol. 2019 Apr;201:48-54. doi: 10.1016/j.clim.2019.02.011. Epub 2019 Feb 25.
5
Results from a randomized trial combining trastuzumab with a peptide vaccine suggest a role for HER2-targeted therapy in triple-negative breast cancer.
Oncotarget. 2021 Nov 9;12(23):2318-2319. doi: 10.18632/oncotarget.27998.
6
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.
7
HER2-Based Immunotherapy for Breast Cancer.
Cancer Biother Radiopharm. 2018 Jun;33(5):169-175. doi: 10.1089/cbr.2017.2327. Epub 2018 Jun 6.
8
MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer.
J Control Release. 2019 Jun 10;303:223-236. doi: 10.1016/j.jconrel.2019.04.019. Epub 2019 Apr 15.
9
Developing anti-HER2 vaccines: Breast cancer experience.
Int J Cancer. 2018 Nov 1;143(9):2126-2132. doi: 10.1002/ijc.31551. Epub 2018 May 10.
10
Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Breast Cancer Res Treat. 2013 Jul;140(2):273-84. doi: 10.1007/s10549-013-2626-7. Epub 2013 Jul 24.
引用本文的文献
1
Amplifying Immune Responses: Microparticulate Vaccine Approach Against Breast Cancer.
Breast Cancer (Dove Med Press). 2024 Mar 28;16:149-162. doi: 10.2147/BCTT.S441368. eCollection 2024.
2
Novel HER-2 Targeted Therapies in Breast Cancer.
Cancers (Basel). 2023 Dec 23;16(1):87. doi: 10.3390/cancers16010087.
3
Identification of genetic and immune signatures for the recurrence of HER2-positive breast cancer after trastuzumab-based treatment.
Breast Cancer Res Treat. 2023 Jun;199(3):603-615. doi: 10.1007/s10549-023-06931-1. Epub 2023 Apr 21.
4
Targeting HER2 in breast cancer: new drugs and paradigms on the horizon.
Explor Target Antitumor Ther. 2021;2(2):139-155. doi: 10.37349/etat.2021.00037. Epub 2021 Apr 30.
5
Immunological Landscape of HER-2 Positive Breast Cancer.
Cancers (Basel). 2022 Jun 28;14(13):3167. doi: 10.3390/cancers14133167.
6
Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Cancer Control. 2022 Jan-Dec;29:10732748221099230. doi: 10.1177/10732748221099230.
7
Evolution of Cancer Vaccines-Challenges, Achievements, and Future Directions.
Vaccines (Basel). 2021 May 20;9(5):535. doi: 10.3390/vaccines9050535.
本文引用的文献
1
Results of a Randomized Phase IIb Trial of Nelipepimut-S + Trastuzumab versus Trastuzumab to Prevent Recurrences in Patients with High-Risk HER2 Low-Expressing Breast Cancer.
Clin Cancer Res. 2020 Jun 1;26(11):2515-2523. doi: 10.1158/1078-0432.CCR-19-2741. Epub 2020 Feb 18.
2
Efficacy and Safety Analysis of Nelipepimut-S Vaccine to Prevent Breast Cancer Recurrence: A Randomized, Multicenter, Phase III Clinical Trial.
Clin Cancer Res. 2019 Jul 15;25(14):4248-4254. doi: 10.1158/1078-0432.CCR-18-2867. Epub 2019 Apr 29.
3
Application of E75 peptide vaccine in breast cancer patients: A systematic review and meta-analysis.
Eur J Pharmacol. 2018 Jul 15;831:87-93. doi: 10.1016/j.ejphar.2018.05.010. Epub 2018 May 9.
4
A pilot study of the immunogenicity of a 9-peptide breast cancer vaccine plus poly-ICLC in early stage breast cancer.
J Immunother Cancer. 2017 Nov 21;5(1):92. doi: 10.1186/s40425-017-0295-5.
5
A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice.
J Drug Target. 2018 Apr;26(4):365-372. doi: 10.1080/1061186X.2017.1387788. Epub 2017 Oct 18.
6
Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 DCIS Independent of Route: Results of Randomized Selection Design Trial.
Clin Cancer Res. 2017 Jun 15;23(12):2961-2971. doi: 10.1158/1078-0432.CCR-16-1924. Epub 2016 Dec 13.
7
The development and use of the E75 (HER2 369-377) peptide vaccine.
Future Oncol. 2016 Jun;12(11):1321-9. doi: 10.2217/fon-2015-0054. Epub 2016 Apr 5.
8
Final report of the phase I/II clinical trial of the E75 (nelipepimut-S) vaccine with booster inoculations to prevent disease recurrence in high-risk breast cancer patients.
Ann Oncol. 2014 Sep;25(9):1735-1742. doi: 10.1093/annonc/mdu211. Epub 2014 Jun 6.
9
Clinical trial results of the HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Cancer. 2012 May 15;118(10):2594-602. doi: 10.1002/cncr.26574. Epub 2011 Oct 11.
10
Use of booster inoculations to sustain the clinical effect of an adjuvant breast cancer vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02.
Cancer. 2011 Feb 1;117(3):463-71. doi: 10.1002/cncr.25586. Epub 2010 Sep 15.
Zotero 插件